BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26028097)

  • 21. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
    Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L
    J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer.
    Zhao R; Chen G
    Int J Clin Exp Pathol; 2015; 8(11):14909-16. PubMed ID: 26823821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
    Booton R; Ward T; Heighway J; Ashcroft L; Morris J; Thatcher N
    J Thorac Oncol; 2006 Sep; 1(7):679-83. PubMed ID: 17409936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.
    Bepler G; Kusmartseva I; Sharma S; Gautam A; Cantor A; Sharma A; Simon G
    J Clin Oncol; 2006 Oct; 24(29):4731-7. PubMed ID: 16966686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
    Joerger M; Burgers SA; Baas P; Smit EF; Haitjema TJ; Bard MP; Doodeman VD; Smits PH; Vincent A; Huitema AD; Beijnen JH; Schellens JH
    Cancer; 2012 May; 118(9):2466-75. PubMed ID: 22031394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
    Kwon WS; Rha SY; Choi YH; Lee JO; Park KH; Jung JJ; Kim TS; Jeung HC; Chung HC
    Pharmacogenet Genomics; 2006 Jun; 16(6):429-38. PubMed ID: 16708051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
    Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glutathione S-Transferase Gene Polymorphisms are Associated with an Improved Treatment Response to Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis.
    Wang H; Gao X; Zhang X; Gong W; Peng Z; Wang B; Wang L; Chang S; Ma P; Wang S
    Med Sci Monit; 2018 Oct; 24():7482-7492. PubMed ID: 30341887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.
    Sun N; Sun X; Chen B; Cheng H; Feng J; Cheng L; Lu Z
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):437-46. PubMed ID: 19568750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.
    Vilmar AC; Santoni-Rugiu E; Sorensen JB
    Ann Oncol; 2013 Feb; 24(2):309-314. PubMed ID: 23038758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report.
    Zeng C; Fan W; Zhang X
    Cell Oncol (Dordr); 2015 Aug; 38(4):319-25. PubMed ID: 26092210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
    Rosell R; Felip E; Taron M; Majo J; Mendez P; Sanchez-Ronco M; Queralt C; Sanchez JJ; Maestre J
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
    Rosell R; Crino L; Danenberg K; Scagliotti G; Bepler G; Taron M; Alberola V; Provencio M; Camps C; De Marinis F; Sanchez JJ; Peñas R
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):19-25. PubMed ID: 12917817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
    Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
    Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y
    Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum.
    Wang LR; Zhang GB; Chen J; Li J; Li MW; Xu N; Wang Y; Shen Tu JZ
    J Zhejiang Univ Sci B; 2011 Mar; 12(3):174-9. PubMed ID: 21370501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer.
    Lv H; Han T; Shi X; Yao Y; Yao Y; Qiu W; Yue L; Liang J
    Med Oncol; 2014 Aug; 31(8):86. PubMed ID: 24958519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
    Gao Z; Han B; Shen J; Gu A; Zhong H
    Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):340-4. PubMed ID: 21496433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
    Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
    Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.